Trenton, December 19, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, issued the following statement concerning today’s White House announcement on drug pricing agreements:
“New Jersey’s and America’s life sciences companies have again affirmed their commitment to lowering costs for patients around the country. These companies voluntarily negotiate agreements to responsibly lower costs in ways that don’t jeopardize the discovery of future life-saving treatment and cures.”
Buteas continued, “Our industry is doing our share to lower costs – not only with today’s announcement, but also by keeping people healthy so they avoid costly surgeries, hospitalizations and long-term care facilities. It’s time for other healthcare sectors to do their part: PBMs and insurance companies should take the billions of dollars pharmaceutical companies rebate them, and give those rebates directly to patients, as intended. We will work with all stakeholders to continue lowering costs while still curing diseases.”